Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia

Clinical trial NCT01541943 · COMPLETED

Trial details

NCT number: NCT01541943
Sponsor: HanAll BioPharma Co., Ltd.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Essential Hypertension Hyperlipidemia

Start date: 2012-03-01
Primary completion: 2014-11-01
Enrollment: 356

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.